(BONEX) Bonesupport Holding - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0009858152

Injectable Bio-Ceramic, Bone Graft, Bone Void Filler

BONEX EPS (Earnings per Share)

EPS (Earnings per Share) of BONEX over the last years for every Quarter: "2020-03": -0.56, "2020-06": -0.41, "2020-09": -0.33, "2020-12": -0.43, "2021-03": -0.32, "2021-06": -0.42, "2021-09": -0.22, "2021-12": -0.38, "2022-03": -0.25, "2022-06": -0.25, "2022-09": -0.23, "2022-12": -0.32, "2023-03": 0, "2023-06": 0.08, "2023-09": 3.47, "2023-12": 0.16, "2024-03": 0.33, "2024-06": 0.41, "2024-09": 0.46, "2024-12": 0.81, "2025-03": 0.16,

BONEX Revenue

Revenue of BONEX over the last years for every Quarter: 2020-03: 43.432, 2020-06: 36.175, 2020-09: 48.078, 2020-12: 53.175, 2021-03: 44.829, 2021-06: 51.777, 2021-09: 54.877, 2021-12: 61.402, 2022-03: 66.342, 2022-06: 74.632, 2022-09: 84.623, 2022-12: 103.221, 2023-03: 119.742, 2023-06: 140.388, 2023-09: 158.204, 2023-12: 172.743, 2024-03: 184.419, 2024-06: 219.795, 2024-09: 237.503, 2024-12: 257.01, 2025-03: 283.544,

Description: BONEX Bonesupport Holding

Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. The companys product portfolio includes CERAMENT Bone Void Filler, CERAMENT G, and CERAMENT V, which are designed to remodel to host bone and, in some cases, elute antibiotics to prevent and treat bone infections.

The companys products are used in various orthopedic applications, including trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. With a strong presence in Europe, North America, and internationally, Bonesupport Holding AB has established itself as a player in the biotechnology industry. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and the successful development of preclinical product candidates.

From a financial perspective, Bonesupport Holding ABs market capitalization stands at approximately 19.5 billion SEK, with a return on equity (RoE) of 17.73%. The companys high P/E ratio of 161.20 suggests that investors have high expectations for future growth. To meet these expectations, Bonesupport Holding AB will need to continue to innovate and expand its product offerings, while also demonstrating strong commercial execution and operational efficiency.

Some key metrics to monitor include the companys sales growth trajectory, its ability to expand its product pipeline, and its progress in achieving regulatory approvals for new products. Additionally, investors should keep an eye on the competitive landscape and the companys ability to maintain its market share in the face of competition from other orthobiologics companies.

Additional Sources for BONEX Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

BONEX Stock Overview

Market Cap in USD 2,318m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Biotechnology
IPO / Inception

BONEX Stock Ratings

Growth Rating 68.4
Fundamental 77.9
Dividend Rating 0.0
Rel. Strength 34.5
Analysts -
Fair Price Momentum 419.06 SEK
Fair Price DCF 65.86 SEK

BONEX Dividends

Currently no dividends paid

BONEX Growth Ratios

Growth Correlation 3m 32.2%
Growth Correlation 12m -18.2%
Growth Correlation 5y 88.3%
CAGR 5y 50.15%
CAGR/Max DD 5y 0.86
Sharpe Ratio 12m -0.09
Alpha 7.54
Beta 0.170
Volatility 44.72%
Current Volume 155.8k
Average Volume 20d 159.8k
Stop Loss 329 (-3.2%)
What is the price of BONEX shares?
As of July 31, 2025, the stock is trading at SEK 340.00 with a total of 155,828 shares traded.
Over the past week, the price has changed by +8.49%, over one month by +21.43%, over three months by +13.71% and over the past year by +15.18%.
Is Bonesupport Holding a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Bonesupport Holding (ST:BONEX) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 77.86 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BONEX is around 419.06 SEK . This means that BONEX is currently undervalued and has a potential upside of +23.25% (Margin of Safety).
Is BONEX a buy, sell or hold?
Bonesupport Holding has no consensus analysts rating.
What are the forecasts for BONEX share price target?
According to our own proprietary Forecast Model, BONEX Bonesupport Holding will be worth about 458.3 in July 2026. The stock is currently trading at 340.00. This means that the stock has a potential upside of +34.79%.
Issuer Target Up/Down from current
Wallstreet Target Price 421.2 23.9%
Analysts Target Price - -
ValueRay Target Price 458.3 34.8%